Urgent.News

What's breaking now, across thousands of outlets.

Health & Medicine

Darolutamide Improves Metastasis-Free Survival in Very High-Risk Prostate Cancer

(MedPage Today) -- Adding darolutamide (Nubeqa) to androgen deprivation therapy (ADT) and radiation therapy significantly improved metastasis-free survival in patients with very high-risk prostate cancer, according to findings from the phase III...

Darolutamide Improves Metastasis-Free Survival in Very High-Risk Prostate Cancer

We haven't written up this one. MedPage Today has the full story — the link below goes straight to it.

Read the original at medpagetoday.com →

More in Health & Medicine

More from Wednesday 4 November →